



TetraGraph clinical use and comparison presented in ASA abstract

Uppsala, 21 June 2017. Senzime AB (publ) in partnership with Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TOF-Watch SX and the TetraGraph.

The results will be presented in October at the American Society of Anesthesiologists (ASA) Annual Meeting in Boston, USA. For more than 67 years, the ASA annual meeting has been the most comprehensive anesthesia-related educational event in the world, bringing together top influential and notable professionals in anesthesiology, pain medicine and critical care medicine. ANESTHESIOLOGY 2017 is expected to welcome nearly 15,000 attendees.

“We are very proud and happy that this initial abstract comparing the TetraGraph with the former gold standard product TOF-Watch is to be presented at the ASA. This will give us the opportunity to reach out to thousands of anesthesiologists and show them the latest development in this area and how our product can contribute to improved clinical care, patient safety and lower costs”, says Lena Söderström, CEO of Senzime.

Senzime is exhibiting at the meeting; please visit us at booth #3630.

For further information, please contact:

Lena Söderström, CEO

Tel: +46-708 16 39 12 email: lena.soderstrom@senzime.com

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com